Combined modality therapy of lung cancer

Clinical Cancer Research

Volumn 3, Issue 12 II, 1997, Pages 2638-2647

  Livingston, Robert B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; MITOMYCIN C; NAVELBINE; TAXANE DERIVATIVE; THYMOSIN; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0031418308     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (94)

1. Livingston, R. B., Moore, T. N., Heilbrun, L., Bottomley, R., Lehane, D., Rivkin, S. E., and Thigpen, T. Small-cell carcinoma of the lung: combined chemotherapy and radiation. A Southwest Oncology Group study. Ann. Intern. Med., 88: 194-199, 1978.
2. Holoye, P. Y., and Samuels, M. L. Cyclophosphamide, vincristine and sequential split-course radiotherapy in the treatment of small cell lung cancer. Chest, 67: 675-679, 1975.
3. Kies, M. S., Mira, J. G., Crowley, J. J., Chen, T. T., Pazdur, R., Grozea, P. N., Rivkin, S. E., Coltman, C. A., Jr., Ward, J. H., and Livingston, R. B. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders, and with wide-field versus reduced-field radiation in partial responders. J. Clin. Oncol., 5: 592-600, 1987.
4. White, J. E., Chen, T., McCracken, J., Kennedy, P., Seydel, H. G., Hartman, G., Mira, J., Khan, M., Durrance, F. Y., and Skinner, O. The influence of radiation therapy quality control on survival, response and sites of relapse in oat cell carcinoma of the lung. Cancer (Phila.), 50: 1084-1090, 1982.
5. Cox, J. D., Byhardt, R., Komaki, R., Wilson, J. F., Libnoch, J. A., and Hansen, R. Interaction of thoracic irradiation and chemotherapy on local control and survival in small cell carcinoma. Cancer Treat. Rep., 63: 1251-1255, 1979.
6. Souhami, R. L., Geddes, D. M., Spiro, S. G., Harper, P. G., Tobias, J. S., Mantell, B. S., Fearon, F., and Bradbury, I. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br. Med. J., 288: 1643-1646, 1984.
7. Osterlind, K., Hansen, H. H., Hansen, H. S., Dombernowsky, P., Hansen, M., and Rorth, M. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. Br. J. Cancer, 54: 7-17, 1986.
8. Perry, M. C., Eaton, W. L., Propert, K. J., Ware, J. H., Zimmer, B., Chahinian, A. P., Skarin, A., Carey, R. W., Kreisman, H., Faulkner, C., Comis, R., and Green, M. R. Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung. N. Engl. J. Med., 316: 912-918, 1987.
9. Catane, R., Lichter, A., Lee, Y. J., Brereton, H. D., Schwade, J. G., and Glatstein, E. Small cell lung cancer: analysis of treatment factors contributing to prolonged survival. Cancer (Phila.), 48: 1936-1943, 1981.
10. Johnson, D. H., Bass, D., Einhorn, L. H., Crawford, J., Perez, C. A., Bartolucci, A., Omura, G. A., and Greco, F. A. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J. Clin. Oncol., 11: 1223-1229, 1993.
11. Cavalli, F., Goldhirsch, A., Siegenthaler, P., Kaplan, S., and Beer, N. Phase II study with cis-dichlorodiammineplatinum(II) in small cell anaplastic carcinoma. Eur. J. Cancer, 16: 617-623, 1980.
12. Sierocki, J. S., Hilaris, B. S., Hopfan, S., Martini, N., Barton, B., Golby, R. B., and Wittes, R. E. cis-Dichlorodiammine platinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat. Rep., 63: 1593-1597, 1979.
13. O'Bryan, R. M., Crowley, J. J., Kim, P. N., Epstein, R. B., Neilan, B., Coltman, C. A., Jr., Stuckey, W. J., and Pazdur, R. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group study. Cancer (Phila.), 65: 856-860, 1990.
14. Pedersen, A. G., and Hansen, H. H. Etoposide (VP-16) in the treatment of lung cancer. Cancer Treat. Rev., 10: 245-264, 1983.
15. Leipzig, B. Cisplatin sensitization to radiotherapy of squamous cell carcinomas of the head and neck. Am. J. Surg., 146: 462-465, 1983.
16. Pinedo, H. M., Karim, A. B., Van Vliet, W. H., Snow, G. B., and Vermorken, J. B. Daily cis-dichlorodiammineplatinum(II) as a radio-enhancer: a preliminary toxicity report. J. Cancer Res. Clin. Oncol., 105: 78-82, 1983.
17. McCracken, J. D., Janaki, L. M., Crowley, J. J., Taylor, S. A., Shankir Gira, P. G., Weiss, G. B., Gordon, W., Jr., Baker, L. H., Mansouri, A., and Kuebler, J. P. Concurrent chemotherapy/radiotherapy for limited small cell lung carcinoma: a Southwest Oncology Group study. J. Clin. Oncol., 8: 892-898, 1990.
18. Murray, N., Coy, P., Pater, J. L., Hodson, I., Arnold, A., Zee, B. C., Payne, D., Kostashuk, E. C., Evans, W. K., Dixon, P., Sadura, A., Feld, R., Levitt, M., Wierzbicki, R., Ayoub, J., Maroun, J. A., and Wilson, K. S. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J. Clin. Oncol., 11: 336-344, 1993.
19. Turrisi, A. T., Glover, D. J., Mason, B., and Tester, W. Concurrent twice-daily multi-field radiotherapy and platinum-etoposide chemotherapy for limited small cell lung cancer: update 1988. Proc. Am. Soc. Clin. Oncol., 7: 211, 1988.
20. Morstyn, G., Russo, A., Carney, D. N., Karawya, E., Wilson, S. H., and Mitchell, J. B. Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines. J. Natl. Cancer Inst., 73: 801-807, 1984.
21. Johnson, B. E., Grayson, J., Woods, E., Gazdar, A. F., Anderson, M., Lesar, M., Linnolia, I., Minna, J. D., Glatstein, E., and Ihde, D. C. Limited stage small cell lung cancer treated with concurrent etoposide/ cisplatin plus BID chest radiotherapy. Proc. Am. Soc. Clin. Oncol., 8: 228, 1989.
22. Johnson, B. E., Bridges, J. D., Sobczeck, M., Gray, J., Linnoila, R. I., Gazdar, A. F., Hankins, L., Steinberg, S. M., Edison, M., Frame, J. N., Pass, H., Nesbitt, J., Holden, D., Mulshine, J. L., Glatstein, E., and Ihde, D. C. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J. Clin. Oncol., 14: 806-813, 1996.
23. Johnson, D. H., Kim, K., Sause, W., Komaki, R., Wagner, H., Aisner, S., Livingston, R., Blum, R., and Turrisi, A. T. Cisplatin and etoposide plus thoracic radiotherapy administered once or twice daily in limited stage small cell lung cancer: final report of Intergroup Trial 0096. Proc. Am. Soc. Clin. Oncol., 15: 374, 1996.
24. Byhardt, R. W. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 32: 1513-1525, 1995.
25. Kristjansen, P. E., and Kristensen, C. A. The role of prophylactic cranial irradiation in the management of small cell lung cancer. Cancer Treat. Rev., 19: 3-16, 1993.
26. Rosen, S. T., Makuch, R. W., Lichter, A. S., Ihde, D. C., Matthews, M. J., Minna, J. D., Glatstein, E., and Bunn, P. A., Jr. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response. Am. J. Med., 74: 615-624, 1983.
27. Arriagada, R., Le Chevalier, T., Bone, F., Riviere, A., Chomy, P., Monnet, I., Tardivon, A., Viader, F., Tarayre, M., and Benhamou, S. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J. Natl. Cancer Inst., 87: 183-190, 1995.
28. Catane, R., Schwade, J. G., Yarr, I., Lichter, A. S., Tepper, J. E., Dunnick, N. R., Brody, L., Brereton, H. D., Cohen, M., and Glatstein, E. Follow-up neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 7: 105-109, 1981.
29. Johnson, B. E., Petronas, N., Hayes, W., Grayson, J., Becker, B., Gnepp, D., Rowland, J., Anderson, A., Glatstein, E., and Ihde, D. C. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small cell lung cancer: further follow-up of 6-to 13-year survivors. J. Clin. Oncol., 8: 48-56, 1990.
30. Lee, J. S., Umsawasdi, T., and Lee, Y. Y. Neurotoxicity in longterm survivors of small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 12: 313-321, 1986.
31. Laukkanen, E., Klonoff, H., Allan, B., Graeb, D., and Murray, N. The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae. Int. J. Radiat. Oncol. Biol. Phys., 14: 1109-1117, 1988.
32. Komaki, R., Meyers, C. A., and Cox, J. D. Neuropsychological functioning of patients with small cell lung cancer prior to and shortly following prophylactic cranial irradiation: evidence for pre-existing cognitive impairments. Proc. Am. Soc. Clin. Oncol., 12: 327, 1993.
33. Bunn, P. A., Jr., Crowley, J., Kelly, K., Hazuka, M. B., Beasley, K., Upchurch, C., and Livingston, R. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective Phase III randomized study of the Southwest Oncology Group. J. Clin. Oncol., 13: 1632-1641, 1995.
34. Socinski, M. A., Cannistra, S. A., Elias, A., Antman, K. H., Schnipper, L., and Griffin, J. D. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet, 1: 1194-1198, 1988.
35. Goodman, G. E., Crowley, J., Livingston, R. B., Rivkin, S. E., Albain, K., and McCulloch, J. H. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. J. Clin. Oncol., 9: 453-457, 1991.
36. Elias, A. D., Ayash, L., Frei, E., III, Skarin, A. T., Hunt, M., Wheeler, C., Schwartz, G., Mazanet, R., Tepler, I., Eder, J. P., McCauley, M., Herman, T., Schnipper, L., and Antman, K. H. Intensive combined modality therapy for limited-stage small-cell lung cancer. J. Natl. Cancer Inst., 85: 559-566, 1993.
37. Ettinger, D. S., Finkelstein, D. M., Sarma, R. P., and Johnson, D. H. Phase II study of paclitaxel in patients with extensive disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol., 13: 1430-1435, 1995.
38. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K., and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J. Clin. Oncol., 10: 1225-1229, 1992.
39. Schiller, J. H., Kim, K., Hutson, P., DeVore, R., Glick, J., Stewart, J., and Johnson, D. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol., 14: 2345-2352, 1996.
40. McCracken, J. D., Chen, T., White, J., Samson, M., Stephens, R., Coltman, C. A., Jr., Saiki, J., Lane, M., Bonnet, J., and McGavran, M. Combination chemotherapy, radiotherapy, and BCG immunotherapy in limited small-cell carcinoma of the lung. Cancer (Phila.), 49: 2252-2258, 1982.
41. Scher, H. I., Shank, B., Chapman, R., Geller, N., Pinsky, C., Gralla, R., Kelsen, D., Bosl, G., Golbe, R., Petroni, G., Niedzwiecki, D., Martini, N., Heelan, R., Hollander, P., Hilaris, B., Oettgen, H., and Wittes, R. E. Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. Cancer Res., 48: 1663-1670, 1988.
42. Doyle, A., Martin, J. W., Funa, K., Gazdar, A., Carney, D., Martin, S. E., Linnoila, I., Cuttitta, F., Mulshine, J., and Bunn, P. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small cell lung cancer. J. Exp. Med., 161: 1135-1151, 1985.
43. Funa, K., Gazdar, A. F., Mattson, K., Niiranen, A., Koivuniemi, A., Oberg, K., Wilander, E., Doyle, A., and Linnoila, R. I. Interferon mediated in vivo induction of beta 2 microglobulin on small cell lung cancers and mid-gut carcinoids. Clin. Immunol. Immunopathol., 41: 159-164, 1986.
44. Jett, J. R., Su, J. Q., and Maksymiuk, A. W. Phase III trial of recombinant interferon gamma (rIFN-y) in complete responders (CR) with small cell lung cancer. J. Clin. Oncol., 12: 2321-2326, 1994.
45. Kelly, K., Crowley, J. J., Bunn, P. A., Jr., Hazuka, M. B., Beasley, K., Upchurch, C., Weiss, G. R., Hicks, W. J., Gandara, D. R., Rivkin, S. E., and Livingston, R. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J. Clin. Oncol., 13: 2924-2930. 1995.
46. Grant, S. C., Yao, T. J., Kris, M. G., Rigas, J. R., Pisters, K. M. W., Miller, V., Houghton, A. N., and Chapman, P. B. Long survival following immunization with BEC2 plus BCG after initial therapy for small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol., 15: 555, 1996.
47. Cuttitta, F., Carney, D. N., Mulshine, J., Moody, T. W., Fedorko, J., Fischler, A., and Minna, J. D. Bombesin like peptides can function as autocrine growth factors in human small cell lung cancer. Nature (Lond.), 316: 823-826, 1985.
48. Rozengurt, E. Polypeptide and neuropeptide growth factors: signalling pathways and role in cancer. In: M. Peckman, H. Pinedo, and U. Veronesi (eds.), The Oxford Textbook of Oncology, pp. 12-20. Oxford, United Kingdom: Oxford University Press, 1995.
49. Langdon, S. P., Sethi, T., Ritchie, A., Muir, M., Smyth, J., and Rozengurt, E. Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res., 52: 4554-4557, 1992.
50. 11]Substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res., 57: 51-54, 1997.
51. Dillman, R. O., Seagren, S. L., Propert, K. J., Guerra, J., Eaton, W. L., Perry, M. C., Carey, R. W., Frei, E. F., III, and Green, M. R. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N. Engl. J. Med., 323: 940-945, 1990.
52. Dillman, R. O., Herndon, J., Seagren, S. L., Eaton, W. L., and Green, M. R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J. Natl. Cancer Inst., 88: 1210-1215, 1996.
53. Sause, W. T., Scott, C., Taylor, S., Johnson, D., Livingston, R., Komaki, R., Emami, B., Curran, W. J., Byhardt, R. W., Turrisi, A. T., Dar, A. R., and Cox, J. D. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Group (ECOG) 4588: preliminary results of a Phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J. Natl. Cancer Inst., 87: 198-205, 1995.
54. Le Chevalier, T., Arriagada, R., Quoix, E., Ruffie, P., Martin, M., Tarayre, M., Lacombe-Terrier, M-J., Douillard, J-Y., and Laplanche, A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst., 83: 417-423, 1991.
55. 2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann. Thorac. Surg., 55: 1365-1374, 1993.
56. Burkes, R. L., Ginsberg, R. J., Shepherd, F. A., Blackstein, M. E., Goldberg, M. E., Waters, P. F., Patterson, G. A., Todd, T., Pearson, F. G., Cooper, J. D., Jones, D., and Lockwood, G. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II trial. J. Clin. Oncol., 10: 580-586, 1992.
57. Lad, T., Wagner, H., Piantadosi, S., and the Lung Cancer Study Group. Randomized phase II evaluation of preoperative chemotherapy alone and radiotherapy alone in stage IIIA non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 10: 258, 1991.
58. 2) non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg., 109: 473-483, 1995.
59. Rosell, R., Gómez-Codina, J., Camps, C., Maestre, J., Padille, J., Cantó, A., Mate, J. L., Li, S., Roig, J., Olazábal, A., Canela, M., Ariza, A., Skácel, Z., Morera-Prat, J., and Abad, A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med., 330: 153-158, 1994.
60. Roth, J. A., Fossella, F., Komaki, R., Ryan, M. B., Putnam, J. B., Jr., Lee, J. S., Dhingra, H., De Caro, L., Chasen, M., McGavran, M., Atkinson, E. N., and Hong, W. K. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIa non-small-cell lung cancer. J. Natl. Cancer Inst., 86: 673-680, 1994.
61. Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., and Nijs, A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med., 326: 524-530, 1992.
62. Trovo, M. G., Minatel, E., Franchin, G., Boccieri, M. G., Nascimben, O., Bolzicco, G., Pizzi, G., Torretta, A., Veronesi, A., and Gobitti, C. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 24: 11-15, 1992.
63. Ansari, R., Tokars, R., Fisher, K., Pennington, R., Mantravadin, T., O'Connor, T., Rynard, S., Miller, M., and Einhorn, L. A Phase III study of thoracic irradiation with or without cisplatin in locoregional unresectable non-small cell lung cancer (NSCLC): a Hoosier Oncology Group (HOG) protocol. Proc. Am. Soc. Clin. Oncol., 10: 241, 1991.
64. Soresi, E., Clerici, M., Borghini, U., Zucali, R., Leoni, M., Botturi, M., Zacali, R., Leoni, M., Botturi, M., Vergari, C., Luporini, G., and Scoddia, S. A randomized clinical trial comparing radiation therapy v. radiation therapy plus cis-dichlorodiammine platinum(II) in the treatment of locally advanced non-small cell lung cancer. Semin. Oncol., 15: 20-25, 1988.
65. Blanke, C., Ansari, R., Mantravadi, R., Gonin, R., Tokars, R., Fisher, W., Pennington, K., O'Connor, T., Rynard, S., Miller, M., and Einhorn, L. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J. Clin. Oncol., 13: 1425-1429, 1995.
66. Hazuka, M. B., Crowley, J. J., Bunn, P. A., Jr., O'Rourke, M., Braun, T. J., and Livingston, R. B. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. J. Clin. Oncol., 12: 1814-1820, 1994.
67. Albain, K. S., Crowley, J. J., Turrisi, A. T., III, Gandara, D. R., Farrar, W. B., Clark, J., Beasley, K. R., and Livingston, R. B. Concurrent cisplatin/etoposide plus radiotherapy (PE+RT) for pathologic stage IIIb non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) Phase II study. Proc. Am. Soc. Clin. Oncol., 16: in press, 1997.
68. Byhardt, R. W., Scott, C. B., Ettinger, D. S., Curran, W. J., Doggett, R. L. S., Coughlin, C., Scarantino, C., Rotman, M., and Emami, B. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group, 90-15. Cancer (Phila.), 75: 2337-2344, 1995.
69. Lee, J. S., Scott, C., Komaki, R., Fossella, F. V., Dundas, G. S., McDonald, S., Byhardt, R. W., and Curran, W. J., Jr. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J. Clin. Oncol., 14: 1055-1064, 1996.
70. Faber, L. P., Kittle, C. K., Warren, W. H., Bonomi, P. D., Taylor, S. G., Reddy, S., and Lee, M. S. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann. Thorac. Surg., 47: 669-677, 1989.
71. Weiden, P. L., Piantadosi, S., and the Lung Cancer Study Group. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a Phase II study of the Lung Cancer Study Group. J. Natl. Cancer Inst., 83: 266-272, 1991.
72. Rusch, V. W., Albain, K. S., Crowley, J. J., Rice, T. W., Lonchyna, V., McKenna, R., Jr., Livingston, R. B., Griffin, B. R., and Benfield, J. R. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J. Thorac. Cardiovasc. Surg., 105: 97-106, 1993.
73. Rusch, V. W., Albain, K. S., Crowley, J. J., Rice, T. W., Lonchyna, V., McKenna, R., Jr., Stelzer, K., Livingston, R. B., and the Southwest Oncology Group. Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Ann. Thorac. Surg., 58: 290-295, 1994.
74. Albain, K. S., Rusch, V. W., Crowley, J. J., Rice, T. W., Turrisi, A. T., III, Weick, J. K., Lonchyna, V. A., Presant, C. A., McKenna, R. J., Gandara, D. R., Fosmire, H., Taylor, S. A., Stelzer, K. J., Beasley, K. R., and Livingston, R. B. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. J. Clin. Oncol., 13: 1880-1892, 1995.
75. Wozniak, A. J., Crowley, J. J., Balcerzak, S. P., Weiss, G. R., Laufman, L. R., Baker, L. H., Fisher, R. I., Bearman, S. A., Taylor, S. A., and Livingston, R. B. Randomized phase III trial of cisplatin vs. cisplatin plus Navelbine in treatment of advanced non-small cell lung cancer: report of a Southwest Oncology Group study (SWOG-9308). Proc. Am. Soc. Clin. Oncol., 15: 374, 1996.
76. Bonomi, P., Kim, K., Chang, A., and Johnson, D. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc. Am. Soc. Clin. Oncol., 15: 382, 1996.
77. Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., Bonjo, C. A., Engstrom, P. F., Litwin, S., and Ozols, R. F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a Phase II toxicity, response, and survival analysis (FCCC 93-024). J. Clin. Oncol., 13: 1860-1970, 1995.
78. Vafai, D., Israel, V., Zaretsky, S., and Natale, R. B. Phase I/II trial of combination carboplatin and Taxol in non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 14: 352, 1995.
79. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H., and Taguchi, T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 83: 1164-1168, 1991.
80. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., and Taguchi, T. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10: 16-20, 1992.
81. Perez-Soler, R., Fossella, F. V., Glisson, B. S., Lee, J. S., Murphy, W. K., Shin, D. M., Kemp, B. L., Lee, J. J., Kane, J., Robinson, R. A., Lippman, S. M., Kurie, J. M., Huber, M. H., Raber, M. N., and Hong, W. K. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol., 14: 505-513, 1996.
82. Shepherd, F. A., Gatzemeier, U., Gotfried, M., Weynants, P., Cottier, B., Groen, H., Rosso, R., Mattson, K., Cortes-Funes, H., Tonato, M., Hatty, S., and Voi, M. An extended phase II study of gemcitabine in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 12: 330, 1993.
83. Fossella, F. V., Lippman, S. M., Shin, D. M., Tarassoff, P., Calayag-Jung, M., Perez-Soler, R., Lee, J. S., Murphy, W. K., Glisson, B., Rivera, E., and Hong, W. K. Maximum-tolerated dose defined for single-agent gemcitabine: a Phase 1 dose-escalation study in chemotherapy-naive patients with advanced non-small-cell cancer. J. Clin. Oncol., 15: 310-316, 1997.
84. Fossella, F. V., Lee, J. S., Shin, D. M., Calayag, M., Huber, M., Perez-Soler, R., Murphy, W. K., Lippman, S., Benner, S., Glisson, B., Chasen, M., Hong, W. K., and Raber, M. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J. Clin. Oncol., 12: 645-651, 1995.
85. Rusch, V., Klimstra, D., Venkatraman, E., and Oliver, J. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res., 55: 5038-5042, 1995.
86. Kohn, K. W. Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment-Fifteenth Bruce F. Cain Memorial Award lecture. Cancer Res., 56: 5533-5546, 1996.
87. Blagosklonny, M. V., Giannakakou, P., El-Deiry, W. S., Kingston, D. G. I., Higgs, P. I., Neckers, L., and Fojo, T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res., 57: 130-135, 1997.
88. Rodenhuis, S., and Slebos, R. J. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res., 52: 2665s-2669s, 1992.
89. Rodenhuis, S., Boerrigter, L., Top, B., Slebos, R. J. C., Mooi, W. J., van't Veer, L., and van Zandwijk, N. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J. Clin. Oncol., 15: 285-291, 1997.
90. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50: 5184-5191, 1990.
91. Seidman, A. D., Baselga, J., Yao, T-J., Gilewski, T., Rosen, P. P., and Norton, L. HER-2/neu over-expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 15: 104, 1996.
92. neu. Cancer Res., 50: 794-801, 1996.
93. Holmes, E. C., Gail, M., and the Lung Cancer Study Group. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J. Clin. Oncol., 4: 710-715, 1986.
94. Holmes, E. C. Postoperative chemotherapy for non-small-cell lung cancer. Chest, 103: 30S-34S, 1993.